Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........

Wed, 24th Mar 2010 18:43
New chief executive Duncan Lewis has restructured Vislink's operations so they are based on customer sectors rather than technologies. The core news and entertainment division reported much lower revenues as its major US contract came to an end. The law enforcement division is benefiting from increased spending on surveillance equipment and the marine division is gaining work onshore. Revenues fell from ÂŁ101m to ÂŁ94.7m in 2009. The underlying operating profit declined by two-fifths to ÂŁ5.22m and pre-tax profit slumped from ÂŁ8.77m to ÂŁ4.75m. The dividend is unchanged at 1.25p a share. Net cash was ÂŁ611,000 at the end of 2009. Capitalised development spending increased from ÂŁ2.95m to ÂŁ3.2m. The order book was worth ÂŁ20.3m at the end of 2009. Cost savings will help profits to recover this year. Evolution forecasts that profits will improve to ÂŁ8.6m in 2010. Asia and the Middle East provide the most opportunities. Vislink is ready to make acquisitions and they are likely to be in Asia so that the company has a base in the region. Healthcare and life sciences services provider Source BioScience moved into profit in 2009. There was a swing from a loss of ÂŁ300,000 to a profit of ÂŁ200,000 on revenues that were 11% higher at ÂŁ12.7m. All three divisions made a positive contribution in the year. Source is investing in DNA sequencing equipment and expects this to be a growth area. The outsourced pharma services operation made its first profit. Alliance Pharma reported a 44% increase in revenues to ÂŁ31.2m in 2009 thanks to a combination of organic and acquisitive growth. Pre-exceptional profits jumped from ÂŁ2.4m to ÂŁ8.6m, although that doesn't include a ÂŁ2.8m write-off mainly relating to the capitalised development costs of a drug. Alliance specialises in mature drugs and treatments which have a solid revenue base. Some of its drugs are more than 50 years old but they still have significant revenues. The recent purchase of Cambridge Laboratories for up to ÂŁ16.4m has added cancer drugs to the portfolio. A much-improved second half performance helped eg solutions to return to profit in the year to January 2010. The operations management software supplier reported a 13% increase in revenues to ÂŁ4.15m. A loss of ÂŁ753,000 was turned into a profit of ÂŁ99,000 in 2009. Higher gross margins and cost cutting were behind the improvement. More software licences were sold in the most recent period. Weak construction demand has hit trading at quantity surveyor Baqus and although work is being won it is at lower margins than in the past. The order book is flat at ÂŁ8m. Management had already warned that the interim figures would be disappointing. Revenues fell from ÂŁ3.98m to ÂŁ3.85m in the six months to December 2009. A profit of ÂŁ365,000 has turned into a loss of ÂŁ470,000, including an exceptional charge for redundancies and office closures.

Related News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

Alliance Pharma News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

Alliance Pharma agrees to take-private deal
10 Mar 2025

Alliance Pharma agrees to take-private deal

(Sharecast News) - Speciality drugmaker Alliance Pharma has agreed to be taken private in a deal valued at more than £360.0m.

Alliance Pharma expects to post flat annual profit, revenue decline
31 Jan 2025

Alliance Pharma expects to post flat annual profit, revenue decline

(Alliance News) - Alliance Pharma PLC on Friday said it expects to report 2024 profit broadly in line with the year before, despite a decline in annua...

LONDON BROKER RATINGS: Jefferies likes Volex; UBS raises Next
31 Jan 2025

LONDON BROKER RATINGS: Jefferies likes Volex; UBS raises Next

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: